Trials / Terminated
TerminatedNCT04928430
Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19
An International, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of 150 mg XAV-19 Infusion, in Patients With Moderate to Severe COVID-19: the EUROXAV Study
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 290 (actual)
- Sponsor
- Xenothera SAS · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of XAV-19 drug in patients with moderate-to-severe COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XAV-19 | 150 mg of XAV-19 single IV perfusion |
| DRUG | Placebo | Single IV infusion |
Timeline
- Start date
- 2021-04-28
- Primary completion
- 2022-11-28
- Completion
- 2022-11-28
- First posted
- 2021-06-16
- Last updated
- 2023-01-23
Locations
18 sites across 5 countries: Bulgaria, Greece, Romania, Spain, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT04928430. Inclusion in this directory is not an endorsement.